Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EMN 2018 | Clonal evolution in MM: MGUS and SMM

Nicola Giuliani • 19 Apr 2018
EMN 2018
Multiple Myeloma Rare Diseases Smoldering Myeloma

Nicola Giuliani, MD, PhD, from the University of Parma, Parma, Italy, talks about the clinical approach required when identifying and treating patients with smoldering myeloma. Dr Giuliani was speaking at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy.

More from Nicola Giuliani

Targeting glutamine/glutamate metabolism to improve bone disease in patients with multiple myeloma 1:08
Targeting glutamine/glutamate metabolism to improve bone disease in patients with multiple myeloma
Nicola Giuliani • 26 Aug 2022
Impact of impaired glutamine/glutamate metabolic axis on osteoclast activation in multiple myeloma 1:32
Impact of impaired glutamine/glutamate metabolic axis on osteoclast activation in multiple myeloma
Nicola Giuliani • 26 Aug 2022
Glutamine metabolism as a diagnostic tool for bone disease in patients with multiple myeloma 2:48
Glutamine metabolism as a diagnostic tool for bone disease in patients with multiple myeloma
Nicola Giuliani • 26 Aug 2022
Therapeutic options for smoldering myeloma 1:39
Therapeutic options for smoldering myeloma
Nicola Giuliani • 19 Apr 2018

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals